Obesity Featured Articles

1. Zymeworks Shares Its Design Rationale (And Wins) In Early-Phase ADC Trials 3/24/2026

   Zymeworks CMO Sabeen Mekan, MD, explores how scientific gains in ADC therapies have influenced first-in‑human trial design.

2. A Clinical Machine Learning Operations (MLOps) Maturity Framework For Biopharma 3/24/2026

   Pharma has invested substantially in machine learning applications, but investment in the operational infrastructure — the MLOps layer — has lagged. The time to build that infrastructure is now — not after your next trial fails.

3. CROs, AI, And The New Economics Of Outsourcing 3/23/2026

   AI and automation are starting to reshape clinical trial outsourcing, but not disrupt it — yet. As CRO consultant Joel White notes, revenues remain strong as trial activity rises, with efficiency gains showing up in margins rather than reduced demand. Large site networks may erode some site-facing work, but won’t replace full-service CROs. The real shift is in how value is captured, and the key signal to watch is whether CRO revenues begin to lag behind trial activity.

4. Don't Let The Nocebo Effect In Psychedelic Trials Become A Regulatory Problem 3/23/2026

   When a patient feels no effect or a worsening effect because a known treatment effect was or wasn't experience, that's the "nocebo" effect. Strategic Advisor Jama Pittman discusses how this effect could impact regulatory reviews.

5. Early Engagement With Sites: Timing Matters More Than Tools 3/20/2026

   Involving sites earlier in study planning changes how trials unfold. This piece explores how timing influences alignment, execution, and day-to-day delivery across the clinical research lifecycle.

6. Are You Liable? What All Clinical Stage Companies Should Understand About Risk Disclosure 3/20/2026

   Barnes & Thornburg partner Seth Mailhot provides a primer on risk disclosure and how sponsor companies can prepare for and mitigate issues that might arise.

7. Old Habits, Communication Issues Still Stalling Site Budget Negotiations 3/19/2026

   Drawing from the 2025 SCRS Landscape Survey Report, Jimmy Bechtel and Ken Getz unpack how growing trial complexity, inconsistent fair market value benchmarks, and structural disconnects are reshaping site-sponsor relationships.

8. Trial Participant Tax Compliance Is A Serious Burden — Make It Ours 3/18/2026

   Learn how strategic payment structures can reduce tax exposure for participants, protect benefit eligibility, and simplify global operations.

9. How To Reduce Eligibility Risk And Prevent Protocol Deviations 3/18/2026

   Eliminate enrollment-based protocol deviations and align with the latest FDA guidance by implementing a centralized, technology-enabled eligibility review to safeguard trial integrity.

10. AI Needs A Home: Inside The Workflows That Drive Trials 3/18/2026

    Move beyond fragmented digital tools. Learn how a governed execution layer transforms AI into a collaborator, streamlining trial decisions and creating a traceable record of human-AI insight.